Ferring Pharmaceuticals has acquired two Phase III orthobiologic product candidates from BioSurface Engineering Technologies, Inc. (BioSET). The drugs, AMPLEX and PREFIX, will be investigated in foot/ankle and lumbar spine fusion surgical procedures, respectively. Both drugs are based on a biomimetic peptide designed to enhance the body’s own natural mechanisms of bone repair.

“With the acquisition of the BioSET portfolio, Ferring intends to build on its growing success in orthopaedics,” said Michel Pettigrew, president of the Ferring executive board and chief operating officer, “By developing new orthobiologic products for joint fusion, we will expand and diversify our offering to include innovative solutions for orthopaedic surgery.”

In addition to AMPLEX and PREFIX, Ferring has acquired a library of rationally designed biomimetic peptides intended for applications in bone and tissue repair.